SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VERISANTE TECHNOLOGY

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: andre dallaire5/8/2012 10:30:59 AM
   of 254
 
Verisante Technology completes Aura beta units
Ticker Symbol: C:VRS Verisante Technology completes Aura beta units Verisante Technology Inc (C:VRS)
Shares Issued 64,802,232
Last Close 5/7/2012 $0.55
Tuesday May 08 2012 - News Release

Mr. Thomas Braun reports

VERISANTE TECHNOLOGY, INC. ANNOUNCES COMPLETION OF BETA UNITS

Verisante Technology Inc. has completed the design and fabrication of the beta version of Verisante Aura. The units are intended for safety and field testing as a final step prior to the commencement of commercial production later this year.

"The completion of these beta units represents a key milestone in bringing a commercial version of Verisante Aura(TM) to market," said Thomas Braun, CEO, Verisante Technology, Inc. "The units include innovative and award-winning technologies that help determine whether a skin lesion is cancerous or benign in less than two seconds, providing immediate diagnosis, better patient outcomes and reduced wait-times."

The beta units were designed and assembled at the Company's engineering facility in Richmond, British Columbia. StarFish Medical Inc., Verisante's product development partner, will use two of the units to help develop the mass produced commercial version of the Verisante Aura(TM) for manufacturing and sale.

Today, the Company also announced it has taken on an additional lease to expand its engineering facility by adding approximately 1500 square feet of production and assembly area. The additional space will support research and development and in-house assembly of custom built devices.

Verisante has filed its audited financial statements and Management's Discussion and Analysis for the year ending December 31, 2011. The Company ended 2011 with a cash position of $5.8 million, liabilities of $687,000 and working capital of $5.5 million. The year-end filings and all the Company's past filings are available to the public on www.sedar.com.

"Verisante remains in a strong financial position, with enough cash to see the company through to commercialization of the Verisante Aura(TM) later this year," said Braun.

We seek Safe Harbor.

© 2012 Canjex Publishing Ltd.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext